Recent advances in engineered T cell therapies targeting B cell malignancies

Keyphrases

• Clinical Trials 100%
• B-cell Malignancies 100%
• Recent Advances 100%
• Chimeric Antigen Receptor T Cells (CAR-T) 100%
• Engineered T Cells 100%
• Adoptive Cell Therapy 100%
• High Efficiency 50%
• Targeting Cancer 50%
• Response Rate 50%
• Chronic Lymphocytic Leukemia 50%
• T Cells 50%
• Multiple Myeloma 50%
• Non-Hodgkin Lymphoma 50%
• Complete Response Rate 50%
• Highly Active 50%
• Transgenic T-cell Receptor 50%
• Leukemia-lymphoma 50%
• Clinical Work 50%
• Manufacturing Methods 50%
• Slow-growing 50%
• CD19 50%
• Pediatric Acute Lymphoblastic Leukemia 50%
• Plasma Cell Disorders 50%
• Adult Acute Lymphoblastic Leukemia 50%
• B Cell Cancer 50%
• T Cell Targeting 50%
• Synthetic Receptors 50%
• Target Selection 50%
• Cell Therapy Product 50%
• Autologous T Cell 50%
• Engineered Receptors 50%

Medicine and Dentistry

• B Cell 100%
• Cancer 100%
• T Cell 100%
• Cell Therapy 100%
• Diseases 75%
• Clinical Trial 50%
• Malignant Neoplasm 25%
• B-Cell Chronic Lymphocytic Leukemia 25%
• Receptor 25%
• Pediatrics 25%
• Immunotherapy 25%
• Non-Hodgkin Lymphoma 25%
• Multiple Myeloma 25%
• T Lymphocyte Receptor 25%
• Chimeric Antigen Receptor T-Cell 25%
• Acute Lymphoblastic Leukemia 25%
• Chimeric Antigen Receptor 25%
• Artificial Receptor 25%
• Immunoglobulin Producing Cell 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Diseases 100%
• Clinical Trial 66%
• Chimeric Antigen Receptor 66%
• Receptor 33%
• Malignant Neoplasm 33%
• Chronic Lymphatic Leukemia 33%
• Multiple Myeloma 33%
• Nonhodgkin Lymphoma 33%
• Immunotherapy 33%
• T Lymphocyte Receptor 33%
• Acute Lymphoblastic Leukemia 33%
• Artificial Receptor 33%